Therasonic is a deeptech startup using a technology developed at the CEA and the CNRS, co-founded by Benoit Larrat, PhD and Anthony Novell, whose ambition is to transform the treatment of neurological diseases by improving drug delivery into the brain.
We are very pleased to announce the creation of TheraSonic and the closing of an initial fundraising round of €1m, led by M2care.
This milestone marks the start of a promising collaboration and paves the way for the launch of TheraSonic’s first human clinical trial.
Stay tuned for the next steps in this exciting adventure!
“M2care is proud to co-create and support the TheraSonic project by bringing entrepreneurial skills and funds to TheraSonic. This project is emblematic of the value brought by our venture studio to startups in pre- and post-creation phases to help them develop and move towards seed and Series A financing. We are very pleased to partner with Benoît Larrat, Anthony Novell, CEA Investment, and Gustave Roussy in this ambitious project addressing fundamental health challenges.”
Florence Thueux
M2care, CEO